No connection

Search Results

ITOC vs JNJ

ITOC
iTonic Holdings Ltd.
BEARISH
Price
$0.28
Market Cap
$6.9M
Sector
Healthcare
AI Confidence
95%
JNJ
Johnson & Johnson
NEUTRAL
Price
$237.96
Market Cap
$573.46B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
ITOC
--
JNJ
21.55
Forward P/E
ITOC
--
JNJ
18.9
P/B Ratio
ITOC
0.78
JNJ
7.03
P/S Ratio
ITOC
13.23
JNJ
6.09
EV/EBITDA
ITOC
-0.77
JNJ
17.81

Profitability

Gross Margin
ITOC
62.59%
JNJ
68.08%
Operating Margin
ITOC
-681.94%
JNJ
23.97%
Profit Margin
ITOC
0.0%
JNJ
28.46%
ROE
ITOC
-71.25%
JNJ
35.03%
ROA
ITOC
-40.98%
JNJ
8.68%

Growth

Revenue Growth
ITOC
91.6%
JNJ
9.1%
Earnings Growth
ITOC
--
JNJ
48.6%

Financial Health

Debt/Equity
ITOC
0.02
JNJ
0.6
Current Ratio
ITOC
8.83
JNJ
1.03
Quick Ratio
ITOC
6.95
JNJ
0.69

Dividends

Dividend Yield
ITOC
--
JNJ
2.19%
Payout Ratio
ITOC
0.0%
JNJ
46.6%

AI Verdict

ITOC BEARISH

ITOC presents a high-risk profile characterized by a Piotroski F-Score of 4/9, indicating only marginal stability amidst a catastrophic price collapse. While the company shows strong top-line revenue growth (91.60%) and exceptional short-term liquidity (Current Ratio 8.83), these are completely overshadowed by an unsustainable operating margin of -681.94%. The stock has plummeted from a 52-week high of $32.00 to $0.28, reflecting a total loss of investor confidence and a severe technical breakdown.

Strengths
Strong YoY revenue growth of 91.60%
Very high liquidity with a Current Ratio of 8.83
Low leverage with a Debt/Equity ratio of 0.02
Risks
Extreme operational inefficiency (Operating Margin -681.94%)
Catastrophic price depreciation (99% drop from 52-week high)
Negative ROE (-71.25%) and ROA (-40.98%)
JNJ NEUTRAL

JNJ presents a dichotomy between strong profitability and deteriorating fundamental health, evidenced by a weak Piotroski F-Score of 3/9. While the company maintains an impressive ROE of 35.03% and a consistent history of earnings beats, the current price of $237.96 trades at a significant premium to its Graham Number of $91.72. Growth remains robust on a YoY basis, but bearish insider sentiment and a very weak technical trend (10/100) suggest immediate headwinds. The stock is fundamentally sound in terms of earnings power but shows signs of operational inefficiency or declining quality in its deterministic health metrics.

Strengths
Exceptional Return on Equity (ROE) of 35.03%
Strong profit margins (28.46%) and gross margins (68.08%)
Consistent earnings beat track record over 25 quarters
Risks
Weak Piotroski F-Score (3/9) indicating declining fundamental health
Bearish insider activity with $58.35M in net sales and zero buys
Low liquidity indicated by a Quick Ratio of 0.69

Compare Another Pair

ITOC vs JNJ: Head-to-Head Comparison

This page compares iTonic Holdings Ltd. (ITOC) and Johnson & Johnson (JNJ) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile